$CTSO

CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement PRINCETON, N.J., September 23, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blo

Original reporting
Published Sep 23, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 11:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CTSO
Neutral
medium confidence
Mentioned
$CTSO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CTSONeutralLow
01

Why it matters

Regaining compliance removes the immediate risk of delisting, which may improve investor confidence and support the share price.

02

Market read

The filing is a primary disclosure of a compliance event, relevant for short‑term traders monitoring listing‑risk catalysts.

03

What to watch

The company's ongoing efforts to meet market value requirements and upcoming FDA milestones could become more material than the compliance news.

Relevance 4/10Novelty 5/10Timing: today

Background

Cytosorbents (NASDAQ: CTSO) is a medical‑technology firm focused on blood purification devices. It previously fell below Nasdaq's $1.00 bid price threshold and now meets the requirement after ten consecutive trading days.

Company-level read

Ticker impact

$CTSONeutralMedium confidence
Context

Cytosorbents announced it regained compliance with Nasdaq's $1.00 minimum bid price requirement, a listing qualification event.

Expected impact

Potential modest upside or reduced downside risk as investors view compliance positively.

Evidence & confidence

The news removes a near-term delisting risk but does not change fundamentals; impact is limited to market perception.

Market effects

Minimal; compliance news is specific to Cytosorbents and does not affect the broader biotech or medical device sector.

Limited to U.S. Nasdaq-listed small caps.

Low; the event is company‑specific with no broader macro implications.

Counterpoint

Some investors may view the compliance regain as a sign of past weakness and could short on the expectation of limited growth.

Key entities

  • Cytosorbents Corp

    Medical‑technology firm listed on Nasdaq.

  • Nasdaq Listing Qualifications Department

    Entity that monitors and enforces listing standards.

Related articles

$CTSOMed

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

$CTSOMed

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of…

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme

$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.